Vaccines and pharmaceuticals for animal health

Intervacc

Intervacc is a Swedish company which develops vaccines against infectious bacteria, focused on the animal health care market. According to Intervacc’s management, the technology platform can be used to develop vaccines for any bacterial species, in principle. The company’s subsidiary, Nordvacc, distributes veterinary vaccines across the Nordic and Baltic regions, as well as in the Netherlands. Intervacc has been listed on Nasdaq First North since 2017.

Financials

INTERVACC

SEKm 2018 2019 2020
Sales 38 40 42
Sales growth (%) -20 5 5
EBITDA -8 -25 N/A
EBITDA margin (%) -15 -21,3 -62,6
EBIT adj -14 -23 -32
EBIT adj margin (%) -28,5 -59,8 -78,3
Pretax profit -23 -32 2
EPS rep -0,49 -0,84 0,04
EPS growth (%) 57,5 -73,5 105,1
EPS adj -0,49 -0,84 0,04
DPS 0 0 0
EV/EBITDA (x) -35,8 -10,9 31,6
EV/EBIT adj (x) -12,7 -8,7 140,2
P/E (x) -17 -9,8 192,6
P/E adj (x) -17 -9,8 192,6
EV/sales (x) 7,6 6,8 6,1
FCF yield (%) -6,1 -7,9 -5,7
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 2,5 1,5 -6,4

Main shareholders

Intervacc

Main shareholders Share capital % Voting shares % Verified
Thomas Eklund 8.9 % 8.9 % 31 Dec 2018
Avanza Pension 7.8 % 7.8 % 31 Dec 2018
Newton Aguiar 7.6 % 7.6 % 18 May 2018
Knutsson Holding AB 5.6 % 5.6 % 31 Dec 2018
Nexttobe AB 5.3 % 5.3 % 31 Dec 2018
K Janzon Holding AB 4.3 % 4.3 % 31 Dec 2018
N.R Bergman Holding AB 4.2 % 4.2 % 31 Dec 2018
Fredrik Lundgren 4.1 % 4.1 % 31 Dec 2018
Björn Sjöstrand 3.3 % 3.3 % 31 Dec 2018
Nordnet Pensionsförsäkring 3.1 % 3.1 % 31 Dec 2018
Source: Holdings by Modular Finance AB

Insider list

Intervacc

Name
Bacilltech Aktiebolag
Bacilltech Aktiebolag
Kenneth Jansson
Kenneth Jansson
Kenneth Jansson
Show More